Recently, a new targeted therapy for XLH, i.e., the recombinant human monoclonal antibody against FGF-23 burosumab, has been approved in the United States and Europe and has achieved significantly greater therapeutic effect and safety in patients with XLH than conventional therapy (Imel et al., 2019). This evidence concerns the gene FGF23 and X-linked hypophosphatemia.